Grifols, S.A. (NASDAQ:GRFS) Q3 2025 Earnings Call Transcript
Daniel Segarra: Hello, everyone. My name is Daniel Segarra, and I serve as the Head of Investor Relations and Sustainability and Vice President at Grifols.
Grifols Sa (GRFS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Permian Investment Partners Alex Duran And Scott Hendrickson | 18,190,262 | $170,078,950 | +5% | 19.27% |
| 2. | Millennium Management Israel Englander | 7,122,155 | $66,592,149 | +3% | 0.03% |
| 3. | Armistice Capital Steven Boyd | 2,768,000 | $25,880,800 | +24% | 0.31% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,738,457 | $25,604,573 | -3% | 0.01% |
| 5. | Harris Associates Natixis Global Asset Management | 2,689,100 | $25,143,085 | -2% | 0.03% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 86,466 | $693,457 | 0.14% |
News See All
Grifols, S.A. (GRFS) to Double Plasma Production With New Spain Facility
Grifols, S.A. (NASDAQ:GRFS) tops our list for being one of the hot stocks to buy.
7 Hot Healthcare Stocks to Buy Right Now
The majority of Americans have experienced the annoyance of having their health insurance rejected, frequently without any recourse after contacting carriers by email and phone. Dr.
Grifols, S.A. (NASDAQ:GRFS) Q1 2025 Earnings Call Transcript
Danny Segarra: Hello, everyone. My name is Danny Segarra, and myself as the Head of Investor Relations and Sustained and Vice President, Grifols.
Here’s White Falcon's Views on Grifols, S.A. (GRFS)
White Falcon Capital Management, an investment fund manager, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here.
12 Best Low Price Pharma Stocks To Invest In Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...
Grifols, S.A. (NASDAQ:GRFS) Q1 2024 Earnings Call Transcript
Daniel Segarra: Hello, everyone, and welcome to Grifols' Conference Call. Today, we will be sharing a business update on our first quarter financial results.
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript
Nuria Pascual: Hello, everyone, and welcome to the Grifols Third Quarter 2023 Conference Call. Thank you very much for taking the time to join us today.
Grifols, S.A. (NASDAQ:GRFS) Q2 2023 Earnings Call Transcript
Nuria Pascual: Hello everyone, and welcome to the Grifols' Second Quarter 2023 Conference Call. Thank you very much for taking the time to join us today.
10 Best Pharma Stocks To Buy Now
With a compound annual growth rate (CAGR) of 9.1%, the global pharmaceuticals industry is projected to expand to $1587.1 billion in 2022 from $1454.7 billion in 2021.
Hedge Fund Resource Center